Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

N-of-One and BioDiscovery Partner

Published: Tuesday, March 25, 2014
Last Updated: Tuesday, March 25, 2014
Bookmark and Share
Partnership equips laboratories and oncologists with a foundation for genomic data analysis through to therapeutic options.

BioDiscovery, Inc. and N-of-One announced a partnership to jointly provide integrated genomic analysis interpretation solutions. This partnership will bring together integrated, best-in-class components to enable clinicians to use genomic data generated by laboratories more easily and efficiently to identify targeted therapeutic options appropriate for each specific patient as well as better understand the molecular profile of the patient’s tumor. Financial terms of the agreement are not disclosed. 

Under the terms of the agreement, N-of-One and BioDiscovery will jointly market and sell N-of-One’s interpretation solutions and content together with BioDiscovery’s genomic analysis software, providing laboratories and oncologists with an integrated platform from genomic data analysis through to therapeutic decision support. 

“The number of genomic variants identified as prognostic indicators, or available as possible therapeutic targets, continues to increase at a very fast rate. BioDiscovery’s solutions excel at helping cytogenetic and molecular laboratories quickly identify likely actionable variants from the thousands present in typical cancer cases, with a particular emphasis on copy number variants (CNVs) that drive a large number of tumor types but remain difficult to interpret”, said Dr. Soheil Shams, CEO, BioDiscovery, Inc. “N-of-One completes the solution by taking this narrowed list and elucidating the possible therapeutic options based on an understanding of these variants in the context of the disease biology.” 

“We are committed to our mission of enabling precision medicine for clinicians and researchers by providing outstanding molecular interpretation,” said Chris Cournoyer, CEO, at N-of-One. “Working with BioDiscovery, developer of genomics visualization and analysis software that is already in use at many cancer centers, hospitals, and independent laboratories, we are able to strengthen the point-of-care by adding a wealth of disease-specific knowledge from the latest research findings and drug trials. This gives oncologists and treating clinicians additional insights into possible therapeutic strategies that are informed by the patient’s disease, genomic profile, available therapies and trials, and current research.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioDiscovery Awarded National Institutes of Health SBIR Grant
SBIR Phase I grant to improve the copy number variation data from TCGA.
Thursday, July 10, 2014
Cancer Centers Renew and Expand BioDiscovery’s Nexus Copy Number Software Licenses
BioDiscovery announces a number of license renewals and expansions of its Nexus Copy Number product at leading cancer research centers.
Wednesday, December 16, 2009
Fox Chase Cancer Center Adopts Nexus Copy Number and Nexus Expression
The center's Keystone Program in Blood Cell Development and Cancer gains a site license for two bioinformatics software programs from BioDiscovery.
Wednesday, February 11, 2009
Scientific News
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
The Mystery of the Instant Noodle Chromosomes
Researchers from the Lomonosov Moscow State University evaluated the benefits of placing the DNA on the principle of spaghetti.
Web App Helps Researchers Explore Cancer Genetics
Brown University computer scientists have developed a new interactive tool to help researchers and clinicians explore the genetic underpinnings of cancer.
An Innovative Algorithm to Decipher How Drugs Work Inside the Body
Researchers at Columbia University Medical Center (CUMC) have developed a computer algorithm that is helping scientists see how drugs produce pharmacological effects inside the body.
How do Networks Shape the Spread of Disease and Gossip?
A team of mathematicians from Oxford University, University of North Carolina at Chapel Hill, and Rutgers University used a set of mathematical rules to encode how a contagion spreads, and then studied the outcomes of these rules.
AncestryDNA and Calico to Research the Genetics of Human Lifespan
Collaboration will analyze family history and genetics to facilitate development of cutting-edge therapeutics.
Informatics Tool Helps Scientists Prioritize Protein Modification Research
Researchers have developed a new informatics technology that analyzes existing data repositories of protein modifications and 3D protein structures to help scientists identify and target research on "hotspots" most likely to be important for biological function.
Software Differences can Skew Medical Scan Results
Differences in software can significantly skew results of medical scans commonly used in clinical care and research.
AMRI, PerkinElmer to Collaborate on Drug Discovery
Albany Molecular Research (AMRI) and PerkinElmer are collaborating to provide drug discovery infrastructure and services in AMRI's newly launched drug discovery center.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!